Related Experiment Video
Updated: May 5, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
Patrick Marcellin1, Ferruccio Bonino, George K K Lau
1Service d'Hépatologie, U773-CRB3, Hôpital Beaujon, University of Paris, Clichy, France. patrick.marcellin@bjn.ap-hop-paris.fr
Background & Aims:
Patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treated with peginterferon alpha-2a with or without lamivudine achieve significantly higher 6-month posttreatment rates of response compared with those treated with lamivudine alone. The durability of
Methods:
Patients received peginterferon alpha-2a only (180 microg once weekly; n = 177), in combination with lamivudine (100 mg daily; n = 179) or lamivudine alone (n = 181) for 48 weeks. A total of 315 patients (116, 114, and 85, respectively) participated in this posttreatment observational study.
Results:
Three years after treatment, the percentage of patients with normal alanine aminotransferase (ATL) was higher for patients treated with peginterferon alpha-2a (31%) than with lamivudine (18%; P = 0.032). Similarly, 28% of patients treated with peginterferon had hepatitis B virus (HBV) DNA levels
Conclusions:
Biochemical and virologic responses were sustained for
More Related Videos
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction

